FLT3 and acute myeloid leukemia: This observation is of potential translational relevance, as we previously reported that BMX is implicated in resistance to gilteritinib in FLT3-mutated acute myeloid leukemia, and this provides justification for further investigations into the use of TL-895 as a BMX inhibitor in this indication (58–60).